A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect
- 30 September 2004
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 148 (3) , 422-429
- https://doi.org/10.1016/j.ahj.2004.03.041
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Prevention of radiocontrast-induced nephropathyCatheterization and Cardiovascular Interventions, 2003
- Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrastCatheterization and Cardiovascular Interventions, 2003
- A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiographyKidney International, 2002
- Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathyCatheterization and Cardiovascular Interventions, 2002
- Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedureJournal of the American College of Cardiology, 2002
- N-acetylcysteine improves coronary and peripheral vascular functionJournal of the American College of Cardiology, 2001
- The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiencyJournal of the American College of Cardiology, 2000
- Prevention of Radiographic-Contrast-Agent–Induced Reductions in Renal Function by AcetylcysteineNew England Journal of Medicine, 2000
- Oxygen free radicals and contrast nephropathy.American Journal of Kidney Diseases, 1998
- Oxidant mechanisms in toxic acute renal failureAmerican Journal of Kidney Diseases, 1997